NextPlat (NXPL)
NASDAQ:NXPL
Want to see NXPL full AI Analyst Report?
Top Page
NextPlat
(NASDAQ:NXPL)
Select Model
Select Model
Rating:56Neutral
Price Target:
$6.50
▲(965.57% Upside)
Action:ReiteratedDate:04/30/26
The score is held back primarily by weak financial performance (ongoing losses, cash burn, and margin pressure). Offsetting this, technicals are supportive with price above key moving averages and positive MACD, and corporate events point to a credible near-term improvement in margins and reduced listing risk; valuation remains constrained by a negative P/E and no dividend.
Positive Factors
Higher-margin contracted healthcare services
Management’s strategic shift toward contracted healthcare services (including new 340B and medication fulfillment contracts) materially raises segment margins and reduces reliance on lower-margin retail pharmacy sales. Higher, contract-backed margins improve long-term profitability sustainability and make break-even targets more attainable as contracts scale and onboarding completes.
Negative Factors
Persistent negative cash flow
Consistent negative operating and free cash flow increases dependence on external financing and limits reinvestment capacity. Even as operating losses narrow, recurring cash burn constrains the company's ability to scale contract operations, fund working capital, and absorb onboarding timing mismatches without further capital injections or expense cuts.
Read all positive and negative factors
Positive Factors
Negative Factors
Higher-margin contracted healthcare services
Management’s strategic shift toward contracted healthcare services (including new 340B and medication fulfillment contracts) materially raises segment margins and reduces reliance on lower-margin retail pharmacy sales. Higher, contract-backed margins improve long-term profitability sustainability and make break-even targets more attainable as contracts scale and onboarding completes.
Read all positive factors
NextPlat (NXPL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$17.05M
Dividend YieldN/A
Average Volume (3M)307.20K
Price to Earnings (P/E)―
Beta (1Y)0.95
Revenue Growth-17.04%
EPS Growth36.59%
CountryUS
Employees162
SectorTechnology
Sector Strength88
IndustrySoftware - Application
Share Statistics
EPS (TTM)-4.55
Shares Outstanding2,690,000
10 Day Avg. Volume353,303
30 Day Avg. Volume307,201
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.80
Price to Sales (P/S)0.26
P/FCF Ratio-2.24
Enterprise Value/Market Cap0.28
Enterprise Value/Revenue0.09
Enterprise Value/Gross Profit0.59
Enterprise Value/Ebitda-0.49
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
NextPlat Business Overview & Revenue Model
Company Description
NextPlat Corp, together with its subsidiaries, provides mobile satellite services (MSS) solutions for satellite-enabled voice, data, personnel and asset tracking, machine-to-machine, and Internet of Things (IoT) connectivity services in the United...
How the Company Makes Money
NextPlat primarily makes money through (1) product sales and distribution and (2) service-based revenue tied to its e-commerce/marketplace operations and healthcare segment. Product revenue is generated when the company sells consumer and healthca...
NextPlat Earnings Call Summary
Earnings Call Date:Nov 13, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:May 15, 2026
Earnings Call Sentiment Neutral
The earnings call reflects a mixed performance. Despite significant cost reductions and improvements in pharmacy revenue and operational efficiency, the company faced a decline in overall revenue and gross margins, primarily due to the challenges in the Healthcare segment. However, the noted turnarounds in the 340B business and robust sales in the e-commerce segment present a cautiously optimistic outlook.Positive Updates
Pharmacy Revenue Increase
Pharmacy prescription revenues increased by approximately $400,000 or 5% year-over-year, driven by higher reimbursement rates per prescription.
Negative Updates
Revenue Decline
Total revenue for the quarter was $13,800,000, an 11% decrease from the prior year quarter, primarily due to a decline in Healthcare Operations.
Read all updates
Q3-2025 Updates
Positive
Negative
Pharmacy Revenue Increase
Pharmacy prescription revenues increased by approximately $400,000 or 5% year-over-year, driven by higher reimbursement rates per prescription.
Read all positive updates
Company Guidance
During the NextPlat Corp 2025 Third Quarter Earnings Conference Call, the company provided guidance on several key metrics. The company reported a total revenue of $13.8 million for the third quarter, an 11% decrease from the previous year. Despite this decline, pharmacy prescription revenues in the Healthcare Operations segment increased by approximately $400,000 or 5%, driven by higher reimbursement rates per prescription. However, 340B contract revenue saw a significant drop, decreasing from $2.5 million to $600,000. The e-commerce segment experienced a modest 4% revenue decline, totaling $3.7 million, primarily due to lower hardware sales. The company's gross profit margin fell to 19.9% from 23.2% the previous year. Operational improvements led to a nearly 40% reduction in operating expenses, now at $4.7 million. The company also highlighted significant cost savings, including a $200,000 monthly payroll reduction following a headcount decrease of 50 employees. Looking forward, NextPlat Corp aims to achieve operational breakeven in 2026, emphasizing growth in profitable business lines and continued cost management.NextPlat Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
62
Positive
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Mar 2024 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 54.32M | 65.48M | 37.76M | 11.71M | 7.74M |
| Gross Profit | 10.91M | 16.23M | 11.31M | 2.49M | 1.86M |
| EBITDA | -9.86M | -20.15M | -19.68M | -6.71M | -6.29M |
| Net Income | -11.71M | -14.03M | -3.78M | -9.16M | -8.11M |
Balance Sheet | |||||
| Total Assets | 27.46M | 36.48M | 64.47M | 28.64M | 20.57M |
| Cash, Cash Equivalents and Short-Term Investments | 13.71M | 19.96M | 26.31M | 18.89M | 17.27M |
| Total Debt | 1.49M | 2.26M | 3.01M | 1.07M | 365.22K |
| Total Liabilities | 10.04M | 9.68M | 16.38M | 2.87M | 3.03M |
| Stockholders Equity | 17.31M | 26.68M | 32.18M | 25.78M | 17.53M |
Cash Flow | |||||
| Free Cash Flow | -6.20M | -5.65M | -4.24M | -4.32M | -4.32M |
| Operating Cash Flow | -6.13M | -5.46M | -3.60M | -3.60M | -4.09M |
| Investing Cash Flow | 163.00K | -953.00K | 5.20M | -7.72M | -229.31K |
| Financing Cash Flow | -225.00K | 72.00K | 5.86M | 13.01M | 20.82M |
NextPlat Technical Analysis
Positive
0.61
Price Trends
5.06
Positive
5.71
Negative
6.70
Negative
Market Momentum
0.08
Negative
55.10
Neutral
75.15
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NXPL, the sentiment is Positive. The current price of 0.61 is below the 20-day moving average (MA) of 5.00, below the 50-day MA of 5.06, and below the 200-day MA of 6.70, indicating a neutral trend. The MACD of 0.08 indicates Negative momentum. The RSI at 55.10 is Neutral, neither overbought nor oversold. The STOCH value of 75.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NXPL.
NextPlat Risk Analysis
NextPlat disclosed 35 risk factors in its most recent earnings report. NextPlat reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
NextPlat Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
56 Neutral | $17.05M | -1.19 | -37.97% | ― | -17.04% | 36.59% | |
54 Neutral | $17.26M | -3.51 | ― | ― | ― | ― | |
48 Neutral | $158.13M | -0.52 | -195.02% | ― | 43.04% | 59.79% | |
45 Neutral | $11.38M | -0.58 | -91.15% | ― | -35.83% | 53.49% | |
43 Neutral | $7.98M | -2.28 | -174.91% | ― | -2.94% | -614.49% |
* Technology Sector Average
NXPL
NextPlat
6.33
1.03
19.46%
IPM
Intelligent Protection Management
1.85
-0.01
-0.54%
CXAI
CXApp
0.16
-0.99
-85.91%
RYDE
Ryde Group Limited Class A
1.23
0.99
414.64%
WCT
Wellchange Holdings Company Limited
2.05
-10.63
-83.83%
NTCL
NetClass Technology Inc Class A
0.38
-12.19
-96.97%
NextPlat Corporate Events
Business Operations and StrategyFinancial Disclosures
NextPlat Highlights Improving Margins in Turnaround Update
Positive
Apr 29, 2026
On April 29, 2026, NextPlat Corp reported preliminary first-quarter 2026 expectations showing its turnaround plan is gaining traction, with consolidated gross margins projected to exceed 34%, up sharply from about 20% for full-year 2025. Managemen...
Delistings and Listing ChangesRegulatory Filings and Compliance
NextPlat Regains Nasdaq Compliance, Stabilizing Listing Status
Positive
Apr 28, 2026
NextPlat Corp, a global consumer products and services company focused on healthcare and technology solutions delivered via e-commerce and retail channels, also supports businesses in optimizing online sales domestically and abroad. Its operations...
Financial DisclosuresRegulatory Filings and ComplianceStock Split
NextPlat Announces 1-for-10 Reverse Stock Split Implementation
Neutral
Apr 6, 2026
On April 2, 2026, NextPlat Corp filed an amended and restated certificate of incorporation in Nevada to implement a 1-for-10 reverse stock split of its common stock, effective at 12:01 a.m. Eastern Time on April 13, 2026. As a result, every 10 iss...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.